Massie Family Clinic
Promoting Accessibility To Healthcare
PATH Vaccination Clinic at the UC Davis MIND Institute
The Food and Drug Administration amended the emergency use authorization (EUA) of Moderna COVID-19 Vaccine to include the 2024-2025 formula. The Moderna COVID-19 Vaccine includes a monovalent (single) component that corresponds to the Omicron variant XBB.1.5 of SARS-CoV-2. The Moderna COVID-19 Vaccine is authorized for all doses administered to individuals 6 months through 11 years of age to prevent COVID-19. The Moderna COVID-19 Vaccine, Bivalent is no longer authorized for use in the United States.
Two types of COVID-19 vaccines are recommended for use in the United States:
- mRNA vaccines
- Moderna COVID-19 Vaccine (2024–2025 Formula) is authorized for children ages 6 months–11 years; SPIKEVAX is the licensed Moderna product for people ages 12 years and older. These vaccines are hereafter referred to as 2024–2025 Moderna COVID-19 Vaccine.
Recommendations for 2024–2025 Moderna COVID-19 Vaccine
People who are not moderately or severely immunocompromised
Initial vaccination
- Ages 6 months – 4 years: 2 doses of 2024–2025 Moderna
- Ages 5 years and older: 1 dose of 2024–2025 Moderna
Received previous doses of a COVID-19 vaccine
- Ages 6 months – 4 years: 1 or 2 doses of 2024–2025 mRNA vaccine from the same manufacturer as administered for initial vaccination, depending on the vaccine and the number of prior doses.
- Ages 5 years and older: 1 dose of 2024–2025 Moderna.
Additional dose: An additional dose of 2024–2025 COVID-19 vaccine for people ages 65 years and older who are not moderately or severely immunocompromised is NOT currently recommended.
Recommendations for 2024–2025 Moderna COVID-19 Vaccine
People who are moderately or severely immunocompromised
Initial vaccination
- Ages 6 months and older: 3 doses of 2024–2025 Moderna
Received previous doses of a COVID-19 vaccine
- Recommended mRNA vaccine and number of 2024–2025 doses are based on age and vaccination history.
Additional doses: People who are moderately or severely immunocompromised ages 6 months and older may receive 1 or more age-appropriate doses of a 2024–2025 mRNA COVID-19 vaccine.
Here is the information for the 2024-2025 Flu Season
Getting a COVID-19 Vaccine at The MIND Institute Social Story (PDF)
The UC Davis MIND Institute and UC Davis Health are now offering the 2023-24 Moderna and flu vaccinations for individuals with neurodevelopmental disabilities ages 6 months and older.
To schedule a vaccine appointment at the PATH Vaccination Clinic at the UC Davis MIND Institute, please call 916-703-5555.
Resources
Vaccine Preparation (PDF)
Tips for Parents from Child Life Specialists (PDF)
PATH Vaccination Tips and Tricks (PDF)
PATH Vaccination Visual Checklist (PDF)
All individuals with neurodevelopmental disabilities 6 months and older that are scheduled for vaccination. We will also accommodate all children needing sensory support or awaiting medical assessments or diagnosis for neurodevelopmental disabilities. The CDC recommends that all children, including children who have already had COVID-19 or flu, should get vaccinated.
Research has shown the COVID-19 and flu vaccinations to be safe and effective. These vaccinations can prevent severe disease, hospitalization, and death. Side effects are often mild and go away after a few days. Serious side effects are rare.
Individuals with neurodevelopmental disabilities 6 months and older.
Trained staff and Child Life Specialists will work with you and your family to ensure safety. Staff utilize reinforcers, visuals, social stories, and other supports to make the experience as comfortable as possible.
You will be contacted by a Child Life Specialist to help prepare you for the visit and to answer any questions.